STERIS (STE) Heads Into Q1 Earnings With Revenue Growth Expected at 7.7%

STERIS (NYSE: STE) is scheduled to report fiscal first-quarter results after the market close on May 18, 2026, with analysts expecting revenue to rise 7.7% year over year. The medical equipment and services company reported $1.50 billion in revenue last quarter, up 9.2% from a year earlier and slightly above Wall Street estimates. Analysts have largely left their forecasts unchanged over the past 30 days, though STERIS has missed revenue expectations multiple times over the past two years. Recent results from peers were mixed. Zimmer Biomet posted 9.3% year-over-year revenue growth and beat estimates by 0.9%, while CONMED reported a 1.3% revenue decline but topped expectations by 2.1%. Zimmer Biomet shares fell 13.5% after results, while CONMED rose 1.9%. STERIS shares are down 8.2% over the past month, underperforming a 6.1% average gain among diversified surgical equipment and consumables peers. The stock recently traded at $204.28, below the average analyst price target of $279.29.